Century Therapeutics, Inc.
IPSCNasdaq
$2.25
↓ -0.4%Jul 17 close · end-of-day
Price
1Y↑ +276.3%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$435.3M
Enterprise Value
$300.5M
P/E
—
P/S
—
P/B
1.6
EV/EBITDA
—
PEG
—
FCF Yield
-21.9%
Dividend Yield
—
Revenue (TTM)
—
Net Income (TTM)
-$107.8M
Free Cash Flow (TTM)
-$95.5M
Gross Margin
—
Operating Margin
—
Net Margin
—
ROE
-40.7%
ROIC
-70.0%
Debt / Equity
—
Net Cash
$134.8M
Return 1Y
+287.8%
Company profile
Century Therapeutics, Inc. develops transformative allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. The company's lead product candidate is CNTY-101, which targets CD19 for relapsed, refractory B-cell lymphoma. It is also developing a CAR-iNK candidate targeting CD133 + EGFR for recurrent glioblastoma.
- CEO
- Osvaldo Flores
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 170
- Headquarters
- Pennsylvania
- Website
- centurytx.com
Management & directors
- Carr DouglasSVP Finance & Operations
- Russotti GregorySee Remarks
- Cowan ChadChief Scientific Officer
- Pfeiffenberger BrentPresident and CEO
Roles derived from SEC Form 4 filings.
Earnings
IPSC Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue——
Diluted EPS-$0.11↓ -112.4%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | — | — | $5.2M | $2.2M | $6.6M | $109.2M |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$53.9M | -$94.9M | -$133.8M | -$146.5M | -$138.1M | -$17.3M |
| Net income | -$53.6M | -$95.8M | -$130.9M | -$136.7M | -$126.6M | -$9.6M |
| Diluted EPS | -$7.16 | -$2.96 | -$2.96 | -$2.30 | -$1.61 | -$0.14 |
| Operating cash flow | -$41.3M | -$89.0M | $14.1M | -$88.3M | -$110.1M | -$103.9M |
| Free cash flow | -$51.1M | -$134.0M | -$16.6M | -$102.1M | -$110.3M | -$104.7M |
| Gross margin | — | — | — | — | — | — |
| Operating margin | — | — | -2574.2% | -6556.9% | -2096.5% | -15.8% |
| Net margin | — | — | -2518.4% | -6115.1% | -1920.9% | -8.8% |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $771,000.00 | $791,000.00 | $4.2M | $109.2M | $0.00 | $0.00 | $0.00 | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$34.8M | -$34.8M | -$37.3M | $74.2M | -$34.7M | -$36.1M | -$20.7M | -$23.7M |
| Net income | -$31.2M | -$31.2M | -$36.1M | $76.6M | -$32.5M | -$34.4M | -$19.2M | -$21.6M |
| Diluted EPS | -$0.38 | -$0.37 | -$0.41 | $0.89 | -$0.38 | -$0.40 | -$0.25 | -$0.11 |
| Operating cash flow | -$27.3M | -$28.3M | -$24.2M | -$34.6M | -$27.6M | -$25.6M | -$16.1M | -$25.3M |
| Free cash flow | -$27.6M | — | — | -$35.1M | -$27.9M | -$25.8M | -$16.2M | -$25.8M |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | -4507.8% | -4398.1% | -893.7% | 67.9% | — | — | — | — |
| Net margin | -4047.6% | -3947.7% | -864.6% | 70.1% | — | — | — | — |
Company news
Jul 14, 2026
Jun 13, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-06-12 | Russotti Gregory· See Remarks | Sale | 2,584 | $2.23 | $5,767.49 | filing |
| 2026-06-12 | Carr Douglas· SVP Finance & Operations | Sale | 1,654 | $2.23 | $3,691.73 | filing |
| 2026-06-11 | Pfeiffenberger Brent· President and CEO | Tax withholding | 13,849 | $2.24 | $31,021.76 | filing |
| 2026-06-11 | Cowan Chad· Chief Scientific Officer | Tax withholding | 358 | $2.24 | $801.92 | filing |
| 2026-06-08 | Russotti Gregory· See Remarks | Sale | 524 | $2.11 | $1,106.16 | filing |
| 2026-06-08 | Carr Douglas· SVP Finance & Operations | Sale | 249 | $2.11 | $525.64 | filing |
| 2026-06-05 | Pfeiffenberger Brent· President and CEO | Tax withholding | 463 | $2.13 | $986.19 | filing |
| 2026-05-15 | Pfeiffenberger Brent· President and CEO | Tax withholding | 31,172 | $2.34 | $72,942.48 | filing |
| 2026-05-04 | Carr Douglas· SVP Finance & Operations | Sale | 264 | $2.34 | $618.02 | filing |
| 2026-04-01 | Cowan Chad· Chief Scientific Officer | Tax withholding | 1,365 | $2.19 | $2,989.35 | filing |
| 2026-03-12 | Russotti Gregory· See Remarks | Sale | 10,076 | $2.55 | $25,683.72 | filing |
| 2026-03-12 | Carr Douglas· SVP Finance & Operations | Sale | 7,043 | $2.55 | $17,952.61 | filing |
| 2026-03-11 | Pfeiffenberger Brent· President and CEO | Tax withholding | 55,397 | $2.73 | $151,233.81 | filing |
| 2026-03-11 | Cowan Chad· Chief Scientific Officer | Tax withholding | 1,431 | $2.73 | $3,906.63 | filing |
| 2026-03-06 | Pfeiffenberger Brent· President and CEO | Tax withholding | 463 | $2.56 | $1,185.28 | filing |
| 2026-02-13 | Pfeiffenberger Brent· President and CEO | Tax withholding | 31,172 | $1.75 | $54,551.00 | filing |
| 2026-02-03 | Carr Douglas· SVP Finance & Operations | Sale | 323 | $1.82 | $588.51 | filing |
| 2026-02-02 | Cowan Chad· Chief Scientific Officer | Award | 135,000 | $0.00 | $0.00 | filing |
| 2026-02-02 | Carr Douglas· SVP Finance & Operations | Award | 110,000 | $0.00 | $0.00 | filing |
| 2026-02-02 | Pfeiffenberger Brent· President and CEO | Award | 475,000 | $0.00 | $0.00 | filing |
| 2026-02-02 | Russotti Gregory· See Remarks | Award | 135,000 | $0.00 | $0.00 | filing |
| 2026-01-02 | Cowan Chad· Chief Scientific Officer | Tax withholding | 1,611 | $1.00 | $1,602.95 | filing |
| 2025-12-22 | Cowan Chad· Chief Scientific Officer | Buy | 58,060 | $0.85 | $49,252.30 | filing |
| 2025-12-12 | Pfeiffenberger Brent· President and CEO | Buy | 52,000 | $0.58 | $30,352.40 | filing |
| 2025-12-10 | Pfeiffenberger Brent· President and CEO | Tax withholding | 463 | $0.53 | $243.54 | filing |
Showing the latest 25 transactions — full history in the linked SEC filings.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.